Fate Therapeutics received FDA IND clearance for FT-839, its next-generation off-the-shelf CAR T-cell candidate targeting CD19 and CD38 for autoimmune diseases. The clearance moves the program into IND-enabling and early clinical planning. FT-839 represents the company’s continued push toward universal or readily deployable cellular therapies designed to expand access and reduce the manufacturing delays associated with autologous CAR T approaches. Dual targeting with CD19 and CD38 is intended to broaden activity while improving disease control in relevant settings. The IND step is notable for biotech pipeline momentum because it sets a concrete regulatory milestone for a platform-adjacent asset that can potentially be paired with combination regimens and biomarker strategies as clinical data accumulate.